ProSomnus is the leading non-CPAP therapy™ for the treatment of Obstructive Sleep Apnea, a serious medical disease affecting over 1 billion people worldwide that is associated with comorbidities, including heart failure, stroke, hypertension, morbid obesity, and type 2 diabetes. ProSomnus intraoral medical devices are engineered to precisely track the treatment plan and anatomy for each patient. Non-invasive, patient preferred and easy to use, ProSomnus devices have demonstrated excellent efficacy, safety, adherence, and overall outcomes in a growing body of clinical investigations. ProSomnus precision intraoral devices are FDA-cleared, patented, and covered by commercial medical insurance, Medicare, TRICARE and many government-sponsored healthcare plans around the world, representing over 200 million covered lives.
The following ProSomnus process and family of products are protected by patents in the United States and elsewhere. This web page is provided to satisfy the virtual patent marking provisions of various jurisdictions, including but not limited to the virtual patent marking provisions of Section 16 of the America Invents Act. It is also intended to serve as notice under 35 U.S.C. § 287(a).
Other ProSomnus products not listed here may be protected by one or more patents in the United States and elsewhere.
U.S. Patents List
- US 2021-0228320
- US 2022-0019192
- US 2022-0330888
- US 2023-0218242
- US 2023-0277367
Foreign Patents List
- EP 3 487 444 validated in France
- EP 3 487 444 validated in Germany
- EP 3 487 444 validated in United Kingdom